Remus Pharmaceuticals Ltd
Incorporated in 2015, Remus Pharma Ltd is in the business of trading and export of API and Finished Formulations and in Technical consultancy services[1]
- Market Cap ₹ 849 Cr.
- Current Price ₹ 720
- High / Low ₹ 1,385 / 630
- Stock P/E 29.3
- Book Value ₹ 217
- Dividend Yield 0.14 %
- ROCE 19.6 %
- ROE 14.0 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Debtor days have improved from 131 to 63.6 days.
- Company's working capital requirements have reduced from 76.0 days to 54.0 days
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| 213 | 620 | |
| 184 | 575 | |
| Operating Profit | 29 | 46 |
| OPM % | 14% | 7% |
| 3 | 5 | |
| Interest | 0 | 1 |
| Depreciation | 1 | 2 |
| Profit before tax | 30 | 47 |
| Tax % | 20% | 19% |
| 24 | 38 | |
| EPS in Rs | 17.69 | 24.64 |
| Dividend Payout % | 4% | 3% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 191% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 41% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -45% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 14% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Equity Capital | 1 | 6 |
| Reserves | 156 | 250 |
| 14 | 23 | |
| 161 | 154 | |
| Total Liabilities | 333 | 433 |
| 14 | 16 | |
| CWIP | 0 | 0 |
| Investments | 105 | 186 |
| 215 | 231 | |
| Total Assets | 333 | 433 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| 1 | 7 | |
| -25 | -11 | |
| 28 | 6 | |
| Net Cash Flow | 4 | 3 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Debtor Days | 198 | 64 |
| Inventory Days | 96 | 35 |
| Days Payable | 209 | 49 |
| Cash Conversion Cycle | 85 | 50 |
| Working Capital Days | 98 | 54 |
| ROCE % | 20% |
Documents
Announcements
-
Record Date
1 November 2025 - Record date Nov 14, 2025 for 1st interim dividend; Board meeting Nov 10, 2025.
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
9 October 2025 - 58,92,000 bonus shares allotted (1:1) on July 7, 2025; listing July 8; new subsidiary; MD and WTD reappointed.
-
Updates
8 October 2025 - RTA MUFG Intime email changed to investor.helpdesk@in.mpms.mufg.com; service requests via provided web portal.
-
Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter
8 October 2025 - Remus Pharma informs NSE exemption from Reg 27(2) under Reg15(2)(b) due to SME Emerge listing.
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
8 October 2025 - Certificate under Regulation 74(5) for quarter ended 30 Sep 2025 confirming dematerialisation by MUFG Intime.
Annual reports
Concalls
-
Aug 2025TranscriptNotesPPT
-
May 2025Transcript PPT
-
Nov 2024Transcript PPT REC
Busienss Overview:[1][2]
RPL and its group of companies specialize in marketing pharmaceutical products with expertise in Critical Care, Neurology, Cardiology, and Diabetic categories, and recently getting off-patent molecules in various dosage forms and in complex generics. Company gets finished pharmaceutical formulations manufactured on loan license or contract manufacturing